JP2020122011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020122011A5 JP2020122011A5 JP2020081948A JP2020081948A JP2020122011A5 JP 2020122011 A5 JP2020122011 A5 JP 2020122011A5 JP 2020081948 A JP2020081948 A JP 2020081948A JP 2020081948 A JP2020081948 A JP 2020081948A JP 2020122011 A5 JP2020122011 A5 JP 2020122011A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- antibody
- seq
- bone
- bone loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010065687 Bone loss Diseases 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 102000019307 Sclerostin Human genes 0.000 claims 11
- 108050006698 Sclerostin Proteins 0.000 claims 11
- 210000000988 bone and bone Anatomy 0.000 claims 10
- 208000029725 Metabolic bone disease Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 206010049088 Osteopenia Diseases 0.000 claims 8
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- 230000032683 aging Effects 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 210000003625 skull Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 206010028851 Necrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000003054 facial bone Anatomy 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000000736 Amenorrhea Diseases 0.000 claims 1
- 206010001928 Amenorrhoea Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010006956 Calcium deficiency Diseases 0.000 claims 1
- 206010061762 Chondropathy Diseases 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000017670 Juvenile Paget disease Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 208000013612 Parathyroid disease Diseases 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 206010053260 Secondary hyperthyroidism Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000008321 Winchester syndrome Diseases 0.000 claims 1
- 208000022567 adolescent idiopathic scoliosis Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 231100000540 amenorrhea Toxicity 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000037182 bone density Effects 0.000 claims 1
- 244000309466 calf Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015100 cartilage disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000005484 gravity Effects 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 208000024884 ischemic bone disease Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000002865 osteopetrosis Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021195517A JP7361086B2 (ja) | 2005-05-03 | 2021-12-01 | スクレロスチンエピトープ |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67758305P | 2005-05-03 | 2005-05-03 | |
| US60/677,583 | 2005-05-03 | ||
| US77684706P | 2006-02-24 | 2006-02-24 | |
| US60/776,847 | 2006-02-24 | ||
| US78224406P | 2006-03-13 | 2006-03-13 | |
| US60/782,244 | 2006-03-13 | ||
| US79264506P | 2006-04-17 | 2006-04-17 | |
| US60/792,645 | 2006-04-17 | ||
| US11/410,540 US8003108B2 (en) | 2005-05-03 | 2006-04-25 | Sclerostin epitopes |
| US11/410,540 | 2006-04-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018147689A Division JP6858733B2 (ja) | 2005-05-03 | 2018-08-06 | スクレロスチンエピトープ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021195517A Division JP7361086B2 (ja) | 2005-05-03 | 2021-12-01 | スクレロスチンエピトープ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020122011A JP2020122011A (ja) | 2020-08-13 |
| JP2020122011A5 true JP2020122011A5 (Direct) | 2020-11-26 |
| JP7010994B2 JP7010994B2 (ja) | 2022-02-10 |
Family
ID=36956127
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510081A Active JP5680823B2 (ja) | 2005-05-03 | 2006-04-28 | スクレロスチンエピトープ |
| JP2014095921A Pending JP2014177470A (ja) | 2005-05-03 | 2014-05-07 | スクレロスチンエピトープ |
| JP2015192869A Active JP6158268B2 (ja) | 2005-05-03 | 2015-09-30 | スクレロスチンエピトープ |
| JP2017031654A Pending JP2017128583A (ja) | 2005-05-03 | 2017-02-23 | スクレロスチンエピトープ |
| JP2018147689A Active JP6858733B2 (ja) | 2005-05-03 | 2018-08-06 | スクレロスチンエピトープ |
| JP2020081948A Active JP7010994B2 (ja) | 2005-05-03 | 2020-05-07 | スクレロスチンエピトープ |
| JP2021195517A Active JP7361086B2 (ja) | 2005-05-03 | 2021-12-01 | スクレロスチンエピトープ |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510081A Active JP5680823B2 (ja) | 2005-05-03 | 2006-04-28 | スクレロスチンエピトープ |
| JP2014095921A Pending JP2014177470A (ja) | 2005-05-03 | 2014-05-07 | スクレロスチンエピトープ |
| JP2015192869A Active JP6158268B2 (ja) | 2005-05-03 | 2015-09-30 | スクレロスチンエピトープ |
| JP2017031654A Pending JP2017128583A (ja) | 2005-05-03 | 2017-02-23 | スクレロスチンエピトープ |
| JP2018147689A Active JP6858733B2 (ja) | 2005-05-03 | 2018-08-06 | スクレロスチンエピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021195517A Active JP7361086B2 (ja) | 2005-05-03 | 2021-12-01 | スクレロスチンエピトープ |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8003108B2 (Direct) |
| EP (6) | EP1891100A2 (Direct) |
| JP (7) | JP5680823B2 (Direct) |
| CA (1) | CA2607276C (Direct) |
| CY (2) | CY1118977T1 (Direct) |
| DK (2) | DK2301961T4 (Direct) |
| ES (5) | ES2901698T3 (Direct) |
| FI (2) | FI2301961T4 (Direct) |
| HR (2) | HRP20170514T4 (Direct) |
| HU (2) | HUE033718T2 (Direct) |
| LT (2) | LT2251351T (Direct) |
| MX (1) | MX348432B (Direct) |
| MY (1) | MY174493A (Direct) |
| PL (2) | PL2251351T5 (Direct) |
| PT (2) | PT2251351T (Direct) |
| SI (2) | SI2251351T2 (Direct) |
| WO (1) | WO2006119062A2 (Direct) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1133558E (pt) | 1998-11-27 | 2007-01-31 | Ucb Sa | Composições e métodos para aumentar a mineralização óssea |
| US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) * | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| NZ544618A (en) * | 2003-06-16 | 2009-02-28 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US20100226884A1 (en) * | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
| RU2511406C2 (ru) | 2006-06-08 | 2014-04-10 | Чугаи Сейяку Кабусики Кайся | Профилактическое или лекарственное средство для воспалительного заболевания |
| US20100015665A1 (en) * | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
| US20100036091A1 (en) * | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2144613B1 (en) | 2006-12-29 | 2018-03-21 | OstéoQC Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| WO2008101234A2 (en) * | 2007-02-16 | 2008-08-21 | Sloan-Kettering Institute For Cancer Research | Anti ganglioside gd3 antibodies and uses thereof |
| JP2010524846A (ja) * | 2007-03-20 | 2010-07-22 | イーライ リリー アンド カンパニー | 抗スクレロスチン抗体 |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| KR102467302B1 (ko) | 2007-09-26 | 2022-11-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| ES2663077T3 (es) | 2007-11-02 | 2018-04-11 | Novartis Ag | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6) |
| BRPI0821145B8 (pt) | 2007-12-05 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido |
| KR101840994B1 (ko) | 2007-12-05 | 2018-03-21 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| CN101896201A (zh) * | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| AU2009288354A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| JP5139517B2 (ja) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | 抗ｎｒ１０抗体、およびその利用 |
| KR20160062207A (ko) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| EP3674317B1 (en) | 2009-03-19 | 2024-12-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| PL2896404T3 (pl) * | 2009-06-04 | 2017-12-29 | Novartis Ag | Sposoby identyfikacji miejsc koniugacji IgG |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| US20120244147A1 (en) * | 2009-08-17 | 2012-09-27 | Theuer Charles P | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents |
| IN2012DN05101A (Direct) * | 2010-01-19 | 2015-10-23 | Immunomedics Inc | |
| SG185035A1 (en) * | 2010-05-04 | 2012-11-29 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| MX362591B (es) | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| TWI761912B (zh) | 2010-11-30 | 2022-04-21 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| MX2013010011A (es) * | 2011-03-01 | 2014-10-24 | Amgen Inc | Agentes de unión biespecífica. |
| EA029956B1 (ru) | 2011-03-25 | 2018-06-29 | Эмджен Инк. | Кристаллы антител против склеростина и составы на их основе |
| PL3404041T3 (pl) | 2011-04-19 | 2020-12-14 | Amgen Inc. | Sposób leczenia osteoporozy |
| JP2014515759A (ja) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | 扁平上皮がんを治療する方法関連出願 |
| WO2013019954A1 (en) | 2011-08-04 | 2013-02-07 | Amgen Inc. | Method for treating bone gap defects |
| SG10201509629QA (en) | 2011-12-28 | 2015-12-30 | Amgen Inc | Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| JP6770312B2 (ja) * | 2012-07-05 | 2020-10-14 | ユセベ ファルマ ソシエテ アノニム | 骨疾患の治療 |
| US10431325B2 (en) | 2012-08-03 | 2019-10-01 | Novartis Ag | Methods to identify amino acid residues involved in macromolecular binding and uses therefor |
| WO2014036357A1 (en) | 2012-08-31 | 2014-03-06 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| SMT201900339T1 (it) | 2013-02-22 | 2019-07-11 | Medimmune Ltd | Coniugati anticorpo anti-dll3/pbd e loro usi |
| AR094877A1 (es) | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| WO2015031698A1 (en) | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Site-specific antibody conjugation methods and compositions |
| KR20170008202A (ko) | 2014-02-21 | 2017-01-23 | 애브비 스템센트알엑스 엘엘씨 | 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체 |
| SG11201610672YA (en) | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US11813328B2 (en) | 2014-10-23 | 2023-11-14 | Amgen Inc. | Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins |
| WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| WO2016106180A1 (en) | 2014-12-22 | 2016-06-30 | Five Prime Therapeutics, Inc. | Anti-csf1r antibodies for treating pvns |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP6755513B2 (ja) * | 2015-03-13 | 2020-09-16 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | 抗スクレロスチン抗体、その抗原結合フラグメントおよびその医薬用途 |
| PL3283527T3 (pl) | 2015-04-13 | 2021-06-14 | Five Prime Therapeutics, Inc. | Leczenie skojarzone nowotworów |
| MA43918A (fr) | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
| EP4650370A2 (en) | 2015-04-14 | 2025-11-19 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| CL2016000164A1 (es) * | 2016-01-21 | 2016-07-29 | Pontificia Universidad Católica De Chile | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv. |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| EA039540B1 (ru) * | 2016-03-25 | 2022-02-08 | Онкомед Фармасьютикалс, Инк. | Связывающие tigit агенты и варианты их применения |
| JOP20180117B1 (ar) | 2016-07-12 | 2022-03-14 | H Lundbeck As | أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها |
| US20190185556A1 (en) | 2016-08-08 | 2019-06-20 | Amgen Inc. | Method of improving connective tissue attachment using anti-sclerostin antibodies |
| EP3548071A4 (en) | 2016-11-30 | 2020-07-15 | OncoMed Pharmaceuticals, Inc. | CANCER TREATMENT METHODS INCLUDING TIGIT BINDING AGENTS |
| BR112019012731A2 (pt) | 2016-12-21 | 2019-11-26 | Mereo Biopharma 3 Limited | uso de anticorpos antiesclerostina no tratamento de osteogênese imperfeita |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| EP3574010A4 (en) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-SCLEROSTINE ANTIBODIES AND METHODS OF USE |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| AU2018258676B2 (en) | 2017-04-28 | 2024-09-19 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| JP7237022B2 (ja) | 2017-08-01 | 2023-03-10 | アムジエン・インコーポレーテツド | 質量分析法による分析用ポリペプチド試料のリアルタイム調製のためのシステム及び方法 |
| US12025618B2 (en) | 2017-08-01 | 2024-07-02 | Amgen Inc. | Systems and methods for performing a real-time glycan assay of a sample |
| EP3681535A1 (en) | 2017-09-13 | 2020-07-22 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| US12405275B2 (en) | 2018-03-13 | 2025-09-02 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| US12429405B2 (en) | 2018-03-13 | 2025-09-30 | Amgen Inc. | Sequential digestion of polypeptides for mass spectrometric analysis |
| US11466079B2 (en) | 2018-03-30 | 2022-10-11 | Amgen Inc. | C-terminal antibody variants |
| GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
| JP7425041B2 (ja) | 2018-08-10 | 2024-01-30 | アムジエン・インコーポレーテツド | 抗体医薬製剤を作製する方法 |
| JP7769544B2 (ja) | 2018-12-14 | 2025-11-13 | アムジエン・インコーポレーテツド | 勾配によるタンパク質濃度定量を伴う使用のためのシステム適合性方法 |
| EP3924083B1 (en) | 2019-02-14 | 2024-05-15 | Amgen Inc. | Systems and methods for preparing a sample and performing a real-time assay of the sample |
| ES2997116T3 (en) | 2019-02-20 | 2025-02-14 | Amgen Inc | Methods of determining protein stability |
| WO2020180967A1 (en) | 2019-03-04 | 2020-09-10 | Amgen Inc. | In vivo reversibility of high molecular weight species |
| WO2020198538A1 (en) | 2019-03-27 | 2020-10-01 | Amgen Inc. | Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products |
| MX2021014733A (es) | 2019-06-05 | 2022-04-06 | Amgen Inc | Metodos de identificacion de atributos de proteinas terapeuticas. |
| EP4013786A1 (en) | 2019-08-12 | 2022-06-22 | Amgen Inc. | Anti-sclerostin antibody formulations |
| US12497446B2 (en) | 2019-08-13 | 2025-12-16 | The Feinstein Institutes For Medical Research | Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies |
| TWI860426B (zh) | 2019-11-20 | 2024-11-01 | 日商中外製藥股份有限公司 | 含有抗體之製劑 |
| CA3195365A1 (en) | 2020-09-18 | 2022-03-24 | Amgen Inc. | Methods of processing a sample for peptide mapping analysis |
| JP2023549113A (ja) | 2020-11-05 | 2023-11-22 | アムジエン・インコーポレーテツド | タンパク質を処理するための材料及び方法 |
| EP4430174A1 (en) | 2021-11-09 | 2024-09-18 | Amgen Inc. | Production of therapeutic proteins |
| CN121311767A (zh) | 2023-06-14 | 2026-01-09 | 百时美施贵宝公司 | 糖蛋白的近实时唾液酸定量 |
| AR133302A1 (es) | 2023-07-19 | 2025-09-17 | Amgen Inc | Métodos de preparación de amortiguador para una formulación de proteína terapéutica |
| WO2025101602A1 (en) | 2023-11-07 | 2025-05-15 | Amgen Inc. | Methods of analyzing amino acid content of a therapeutic protein |
| WO2025255028A1 (en) | 2024-06-03 | 2025-12-11 | Amgen Inc. | High-throughput liquid chromatography-mass spectrometry-based peptide mapping |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US32011A (en) | 1861-04-09 | Coffee-pot | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5837456A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| AU662304B2 (en) | 1990-10-22 | 1995-08-31 | Fox Chase Cancer Center | DNA construct for providing RNA therapy |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| CA2164505A1 (en) | 1993-06-07 | 1994-12-22 | Phillip W. Berman | Hiv envelope polypeptides |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| JPH10511840A (ja) | 1994-04-29 | 1998-11-17 | クリエイティブ バイオモレキュールズ，インコーポレイテッド | 形態形成タンパク質特異細胞表面レセプターおよびその使用 |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| WO1997044461A2 (en) | 1996-05-22 | 1997-11-27 | Novopharm Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| WO1999006554A2 (en) | 1997-08-01 | 1999-02-11 | Genset | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| PT1133558E (pt) | 1998-11-27 | 2007-01-31 | Ucb Sa | Composições e métodos para aumentar a mineralização óssea |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| AU4851900A (en) | 1999-06-09 | 2000-12-28 | Genentech Inc. | Compositions and methods for the treatment of tumor |
| AU4196801A (en) | 2000-03-02 | 2001-09-12 | Amgen Inc | Chordin-like-2 molecules and uses thereof |
| EP1290169A2 (en) | 2000-06-01 | 2003-03-12 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| JP2004520005A (ja) | 2000-06-19 | 2004-07-08 | エフ．ホフマン−ラ ロシュ アーゲー | オステオレビン遺伝子多型性 |
| CA2421056A1 (en) | 2000-09-01 | 2002-03-28 | Genentech, Inc. | A polypeptide for use as a diagnostic marker for the presence of colon tumours |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| NZ533051A (en) | 2001-12-06 | 2006-10-27 | Biocontrol Systems Inc | Sample collection and testing system |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| JP4662714B2 (ja) | 2002-03-01 | 2011-03-30 | セルテック アール アンド ディー インコーポレイテッド | 骨密度を増減させる方法 |
| WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| EP1572122A4 (en) | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES |
| DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
| FI115753B (fi) | 2002-11-29 | 2005-07-15 | Paloheimo Raija | Menetelmä ja sovitelma kahvijuomien valmistamiseksi |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| ES2379689T3 (es) | 2003-03-14 | 2012-04-30 | Ucb Manufacturing, Inc. A Company Incorporated Under The Laws Of The State Of Delaware | Complejo de esclerostina y nogina o cordina, y agentes que modulan la formación de dicho complejo |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| NZ544618A (en) | 2003-06-16 | 2009-02-28 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US20100015665A1 (en) | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| MX2009008096A (es) | 2007-02-02 | 2009-08-07 | Novartis Ag | Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos. |
| JP2010524846A (ja) | 2007-03-20 | 2010-07-22 | イーライ リリー アンド カンパニー | 抗スクレロスチン抗体 |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| ES2663077T3 (es) | 2007-11-02 | 2018-04-11 | Novartis Ag | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6) |
| CN101896201A (zh) | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
-
2006
- 2006-04-25 US US11/410,540 patent/US8003108B2/en active Active
- 2006-04-28 HU HUE10006930A patent/HUE033718T2/en unknown
- 2006-04-28 DK DK10014373.4T patent/DK2301961T4/da active
- 2006-04-28 ES ES10014360T patent/ES2901698T3/es active Active
- 2006-04-28 ES ES10006930T patent/ES2619709T5/es active Active
- 2006-04-28 CA CA2607276A patent/CA2607276C/en active Active
- 2006-04-28 FI FIEP10014373.4T patent/FI2301961T4/fi active
- 2006-04-28 HR HRP20170514TT patent/HRP20170514T4/hr unknown
- 2006-04-28 JP JP2008510081A patent/JP5680823B2/ja active Active
- 2006-04-28 EP EP06751835A patent/EP1891100A2/en not_active Withdrawn
- 2006-04-28 PL PL10006930.1T patent/PL2251351T5/pl unknown
- 2006-04-28 EP EP10014372.6A patent/EP2295448B2/en active Active
- 2006-04-28 EP EP10014373.4A patent/EP2301961B9/en active Active
- 2006-04-28 EP EP10014361.9A patent/EP2298800B9/en active Active
- 2006-04-28 PT PT100069301T patent/PT2251351T/pt unknown
- 2006-04-28 WO PCT/US2006/016345 patent/WO2006119062A2/en not_active Ceased
- 2006-04-28 EP EP10014360.1A patent/EP2345668B1/en active Active
- 2006-04-28 HU HUE10014373A patent/HUE032092T2/en unknown
- 2006-04-28 SI SI200632158T patent/SI2251351T2/sl unknown
- 2006-04-28 HR HRP20170679TT patent/HRP20170679T4/hr unknown
- 2006-04-28 MX MX2011003958A patent/MX348432B/es unknown
- 2006-04-28 LT LTEP10006930.1T patent/LT2251351T/lt unknown
- 2006-04-28 ES ES10014373T patent/ES2624643T5/es active Active
- 2006-04-28 DK DK10006930.1T patent/DK2251351T4/da active
- 2006-04-28 MY MYPI20093533A patent/MY174493A/en unknown
- 2006-04-28 ES ES10014372T patent/ES2620684T5/es active Active
- 2006-04-28 LT LTEP10014373.4T patent/LT2301961T/lt unknown
- 2006-04-28 PL PL10014373.4T patent/PL2301961T5/pl unknown
- 2006-04-28 PT PT100143734T patent/PT2301961T/pt unknown
- 2006-04-28 SI SI200632170T patent/SI2301961T2/sl unknown
- 2006-04-28 EP EP10006930.1A patent/EP2251351B2/en active Active
- 2006-04-28 ES ES10014361T patent/ES2616985T5/es active Active
- 2006-04-28 FI FIEP10006930.1T patent/FI2251351T4/fi active
-
2011
- 2011-04-28 US US13/096,263 patent/US8715663B2/en active Active
-
2014
- 2014-02-20 US US14/185,590 patent/US9353174B2/en active Active
- 2014-05-07 JP JP2014095921A patent/JP2014177470A/ja active Pending
-
2015
- 2015-09-30 JP JP2015192869A patent/JP6158268B2/ja active Active
-
2017
- 2017-02-23 JP JP2017031654A patent/JP2017128583A/ja active Pending
- 2017-03-31 CY CY20171100393T patent/CY1118977T1/el unknown
- 2017-05-09 CY CY20171100495T patent/CY1119127T1/el unknown
-
2018
- 2018-08-06 JP JP2018147689A patent/JP6858733B2/ja active Active
-
2020
- 2020-05-07 JP JP2020081948A patent/JP7010994B2/ja active Active
-
2021
- 2021-12-01 JP JP2021195517A patent/JP7361086B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020122011A5 (Direct) | ||
| ME02085B (me) | Sklerostin vezujuća sredstva | |
| HRP20170679T1 (hr) | Epitopi sklerostina | |
| JP2015524256A5 (Direct) | ||
| HRP20201438T1 (hr) | Metoda inhibiranja resorpcije kosti | |
| JP2023113836A5 (Direct) | ||
| JP2017505622A5 (Direct) | ||
| RU2009108147A (ru) | Иммуноглобулины | |
| JP2010524489A5 (Direct) | ||
| RU2011101589A (ru) | Антитела против il-6 и их применение | |
| RU2010141584A (ru) | Антитело против csf-1r | |
| JP2014110800A5 (Direct) | ||
| HRP20201266T1 (hr) | Anti fg23 antitijelo i farmaceutski pripravak koji sadrži isto | |
| JP2012070737A5 (Direct) | ||
| JP2018524577A5 (Direct) | ||
| MA31308B1 (fr) | Anticorps antisclerostine. | |
| TW200412982A (en) | Method for promoting bone formation | |
| EP3345925A3 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2011502137A5 (Direct) | ||
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| JP2023093753A5 (Direct) | ||
| JP2005506331A5 (Direct) | ||
| JP2011522856A (ja) | （４−｛［（５−｛［（３−クロロフェニル）メチル］オキシ｝−２−メチルフェニル）カルボニル］アミノ｝−３−メチルフェニル）酢酸の新規な塩 | |
| Yuan et al. | Ridge preservation applying a novel hydrogel for early angiogenesis and osteogenesis evaluation: an experimental study in canine |